265P Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor positive HER2 negative breast cancer (HR+BC)

S.J. Howell; Matthew Krebs; Simon Lord; L. Kenny; A. Bahl; G. Clack; E. Ainscow; H-T Arkenau; J.L. Mansi; C. Palmieri; P. Richards; R. Jeselsohn; Z. Mitri; W.J. Gradishar; S. Sardesai; J. O'Shaughnessy; M. Lehnert; Simak Ali; S. McIntosh; R.C. Coombes

doi:10.1016/j.annonc.2021.08.548

265P Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor positive HER2 negative breast cancer (HR+BC)

S.J. Howell, Matthew Krebs, Simon Lord, L. Kenny, A. Bahl, G. Clack, E. Ainscow, H-T Arkenau, J.L. Mansi, C. Palmieri, P. Richards, R. Jeselsohn, Z. Mitri, W.J. Gradishar, S. Sardesai, J. O'Shaughnessy, M. Lehnert, Simak Ali, S. McIntosh, R.C. Coombes

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Pages (from-to)	S477-S478
Journal	Annals of Oncology
Volume	32
DOIs	https://doi.org/10.1016/j.annonc.2021.08.548
Publication status	Published - 1 Sept 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.annonc.2021.08.548

Cite this

Howell, S. J., Krebs, M., Lord, S., Kenny, L., Bahl, A., Clack, G., Ainscow, E., Arkenau, H.-T., Mansi, J. L., Palmieri, C., Richards, P., Jeselsohn, R., Mitri, Z., Gradishar, W. J., Sardesai, S., O'Shaughnessy, J., Lehnert, M., Ali, S., McIntosh, S., & Coombes, R. C. (2021). 265P Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor positive HER2 negative breast cancer (HR+BC). Annals of Oncology, 32, S477-S478. https://doi.org/10.1016/j.annonc.2021.08.548

@article{e08950ff8fc14842a5475a9791fc7c3f,

title = "265P Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor positive HER2 negative breast cancer (HR+BC)",

author = "S.J. Howell and Matthew Krebs and Simon Lord and L. Kenny and A. Bahl and G. Clack and E. Ainscow and H-T Arkenau and J.L. Mansi and C. Palmieri and P. Richards and R. Jeselsohn and Z. Mitri and W.J. Gradishar and S. Sardesai and J. O'Shaughnessy and M. Lehnert and Simak Ali and S. McIntosh and R.C. Coombes",

year = "2021",

month = sep,

day = "1",

doi = "10.1016/j.annonc.2021.08.548",

language = "English",

volume = "32",

pages = "S477--S478",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier BV",

}

Howell, SJ , Krebs, M, Lord, S, Kenny, L, Bahl, A, Clack, G, Ainscow, E, Arkenau, H-T, Mansi, JL, Palmieri, C, Richards, P, Jeselsohn, R, Mitri, Z, Gradishar, WJ, Sardesai, S, O'Shaughnessy, J, Lehnert, M, Ali, S, McIntosh, S & Coombes, RC 2021, '265P Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor positive HER2 negative breast cancer (HR+BC)', Annals of Oncology, vol. 32, pp. S477-S478. https://doi.org/10.1016/j.annonc.2021.08.548

265P Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor positive HER2 negative breast cancer (HR+BC). / Howell, S.J.; Krebs, Matthew; Lord, Simon et al.
In: Annals of Oncology, Vol. 32, 01.09.2021, p. S477-S478.

Research output: Contribution to journal › Meeting Abstract › peer-review

TY - JOUR

T1 - 265P Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor positive HER2 negative breast cancer (HR+BC)

AU - Howell, S.J.

AU - Krebs, Matthew

AU - Lord, Simon

AU - Kenny, L.

AU - Bahl, A.

AU - Clack, G.

AU - Ainscow, E.

AU - Arkenau, H-T

AU - Mansi, J.L.

AU - Palmieri, C.

AU - Richards, P.

AU - Jeselsohn, R.

AU - Mitri, Z.

AU - Gradishar, W.J.

AU - Sardesai, S.

AU - O'Shaughnessy, J.

AU - Lehnert, M.

AU - Ali, Simak

AU - McIntosh, S.

AU - Coombes, R.C.

PY - 2021/9/1

Y1 - 2021/9/1

U2 - 10.1016/j.annonc.2021.08.548

DO - 10.1016/j.annonc.2021.08.548

M3 - Meeting Abstract

SN - 0923-7534

VL - 32

SP - S477-S478

JO - Annals of Oncology

JF - Annals of Oncology

ER -